Providing guidance on alternative treatments for diffuse large B-cell lymphoma patients in partial remission
Return to Listing
Non-Hodgkin's Lymphoma is one of the most common cancers in Wisconsin. Traditional lymphoma treatments include chemotherapy, radiation therapy, and hematopoietic cell transplantation (HCT). Diffuse large B-cell Lymphoma (DLBCL) is the most common non-Hodgkin's Lymphoma and has dismal outcomes with multi-agent chemotherapies.
The FDA recently approved chimeric antigen receptor (CAR)-T cell therapy for DLBCL patients who relapsed or did not achieve remission after chemotherapy. Because CAR-T cell therapy is new and offers another treatment option for DLBCL patients, there is much interest in comparing it with traditional treatments, particularly with HCT.
This project will give clear guidance on a choice of treatments between auto-HCT and CAR-T cell therapy for DLBCL patients in partial remission. In addition, researchers will develop statistical methods that can be applied to general survival data analysis in oncology studies.
8701 W Watertown Plank Road,
Milwaukee, WI 53226-0509
Governance and Reporting
Maps & Directions
©2021 MEDICAL COLLEGE OF WISCONSIN. ALL RIGHTS RESERVED | MCW.EDU | TERMS & PRIVACY | NON-DISCRIMINATION NOTICE